Eliem Therapeutics Inc
NASDAQ:ELYM

Watchlist Manager
Eliem Therapeutics Inc Logo
Eliem Therapeutics Inc
NASDAQ:ELYM
Watchlist
Price: 8.28 USD 3.76% Market Closed
Market Cap: 553m USD
Have any thoughts about
Eliem Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one ELYM stock under the Base Case scenario is hidden USD. Compared to the current market price of 8.28 USD, Eliem Therapeutics Inc is hidden .

The Intrinsic Value is calculated as the average of DCF and Relative values:

ELYM Intrinsic Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Backtest
Eliem Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ELYM based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about ELYM?
Bearish
Neutral
Bullish

Fundamental Analysis

Intrinsic Value and Risks & Rewards hidden

Sign up to unlock intrinsic valuation and risk & rewards analysis.

Sign Up
Company Quality
HIDDEN
Show
Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Eliem Therapeutics Inc

Provide an overview of the primary business activities
of Eliem Therapeutics Inc.

What unique competitive advantages
does Eliem Therapeutics Inc hold over its rivals?

What risks and challenges
does Eliem Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Eliem Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Eliem Therapeutics Inc.

Provide P/S
for Eliem Therapeutics Inc.

Provide P/E
for Eliem Therapeutics Inc.

Provide P/OCF
for Eliem Therapeutics Inc.

Provide P/FCFE
for Eliem Therapeutics Inc.

Provide P/B
for Eliem Therapeutics Inc.

Provide EV/S
for Eliem Therapeutics Inc.

Provide EV/GP
for Eliem Therapeutics Inc.

Provide EV/EBITDA
for Eliem Therapeutics Inc.

Provide EV/EBIT
for Eliem Therapeutics Inc.

Provide EV/OCF
for Eliem Therapeutics Inc.

Provide EV/FCFF
for Eliem Therapeutics Inc.

Provide EV/IC
for Eliem Therapeutics Inc.

Show me price targets
for Eliem Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Eliem Therapeutics Inc?

How accurate were the past Revenue estimates
for Eliem Therapeutics Inc?

What are the Net Income projections
for Eliem Therapeutics Inc?

How accurate were the past Net Income estimates
for Eliem Therapeutics Inc?

What are the EPS projections
for Eliem Therapeutics Inc?

How accurate were the past EPS estimates
for Eliem Therapeutics Inc?

What are the EBIT projections
for Eliem Therapeutics Inc?

How accurate were the past EBIT estimates
for Eliem Therapeutics Inc?

Compare the revenue forecasts
for Eliem Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Eliem Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Eliem Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Eliem Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Eliem Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Eliem Therapeutics Inc with its peers.

Analyze the financial leverage
of Eliem Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Eliem Therapeutics Inc.

Provide ROE
for Eliem Therapeutics Inc.

Provide ROA
for Eliem Therapeutics Inc.

Provide ROIC
for Eliem Therapeutics Inc.

Provide ROCE
for Eliem Therapeutics Inc.

Provide Gross Margin
for Eliem Therapeutics Inc.

Provide Operating Margin
for Eliem Therapeutics Inc.

Provide Net Margin
for Eliem Therapeutics Inc.

Provide FCF Margin
for Eliem Therapeutics Inc.

Show all solvency ratios
for Eliem Therapeutics Inc.

Provide D/E Ratio
for Eliem Therapeutics Inc.

Provide D/A Ratio
for Eliem Therapeutics Inc.

Provide Interest Coverage Ratio
for Eliem Therapeutics Inc.

Provide Altman Z-Score Ratio
for Eliem Therapeutics Inc.

Provide Quick Ratio
for Eliem Therapeutics Inc.

Provide Current Ratio
for Eliem Therapeutics Inc.

Provide Cash Ratio
for Eliem Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Eliem Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Eliem Therapeutics Inc?

What is the current Free Cash Flow
of Eliem Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Eliem Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Eliem Therapeutics Inc

Current Assets 226m
Cash & Short-Term Investments 223.1m
Other Current Assets 2.9m
Non-Current Assets 21k
PP&E 21k
Current Liabilities 3.7m
Accounts Payable 610k
Accrued Liabilities 3.1m
Efficiency

Earnings Waterfall
Eliem Therapeutics Inc

Revenue
0 USD
Operating Expenses
-69.5m USD
Operating Income
-69.5m USD
Other Expenses
5.3m USD
Net Income
-64.2m USD

Free Cash Flow Analysis
Eliem Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ELYM Profitability Score
Profitability Due Diligence

Eliem Therapeutics Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.

hidden
Profitability
Score

Eliem Therapeutics Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.

ELYM Solvency Score
Solvency Due Diligence

Eliem Therapeutics Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
hidden
Solvency
Score

Eliem Therapeutics Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ELYM Price Targets Summary
Eliem Therapeutics Inc

Wall Street analysts forecast ELYM stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ELYM is 4.5 USD .

Lowest
Price Target
Not Available
Average
Price Target
4.5 USD
46% Downside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ELYM?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for ELYM is hidden .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
HIDDEN
Show
Want to learn more about ELYM dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

ELYM Price
Eliem Therapeutics Inc

1M 1M
+38%
6M 6M
+197%
1Y 1Y
+214%
3Y 3Y
-50%
5Y 5Y
-48%
10Y 10Y
-48%
Annual Price Range
8.28
52w Low
2.45
52w High
10.2
Price Metrics
Average Annual Return -50.56%
Standard Deviation of Annual Returns 26.94%
Max Drawdown -92%
Shares Statistics
Market Capitalization 553m USD
Shares Outstanding 66 790 000
Percentage of Shares Shorted 1.54%

Competitive Landscape

Ownership

ELYM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Eliem Therapeutics Inc Logo
Eliem Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

553m USD

Dividend Yield

0%

Description

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Redmond, Washington and currently employs 19 full-time employees. The company went IPO on 2021-08-10. The firm focuses on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system. The firm offers two lead clinical-stage candidates: ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide (PEA) prodrug developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP). ETX-810 is being evaluated in two Phase II a clinical trial. ETX-155 is a neurosteroid gamma-aminobutyric acid type A (GABAA) receptor positive allosteric modulator (PAM) developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS). The firm provides two programs in addition to its clinical candidates, namely Kv7.2/3 program and anxiolytic.

Contact

WASHINGTON
Redmond
23515 Ne Novelty Hill Road, Suite B221 #125
+14252762300.0
eliemtx.com

IPO

2021-08-10

Employees

19

Officers

See Also

Discover More
What is the Intrinsic Value of one ELYM stock?

The intrinsic value of one ELYM stock under the Base Case scenario is hidden USD.

Is ELYM stock undervalued or overvalued?

Compared to the current market price of 8.28 USD, Eliem Therapeutics Inc is hidden .

Back to Top